KGET logo

CaliPharms, Inc. (KGET) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

KGET representa a CaliPharms, Inc., una empresa del sector Basic Materials con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 57/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 18 mar 2026
Puntuación de IA de 57/100

CaliPharms, Inc. (KGET) Exposición a Materiales y Productos Básicos

CEOEric Watson
Sede CentralTemecula, US
Año de la oferta pública inicial (OPI)2013

CaliPharms, Inc. operates within the evolving medicinal cannabis sector, concentrating on THC and CBD-infused beverages. The company, formerly Kleangas Energy Technologies, shifted its focus in 2017. It faces competition in a dynamic market while striving to establish its brand in the cannabis beverage segment.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 18 mar 2026

Tesis de Inversión

CaliPharms, Inc. presents a high-risk, high-reward investment profile due to its early-stage involvement in the cannabis-infused beverage market. The company's success hinges on its ability to navigate complex regulatory hurdles and establish a strong brand presence. Key value drivers include successful product development, effective marketing, and strategic partnerships. The company's negative P/E ratio of -0.01 and a profit margin of -11861.4% indicate significant financial challenges. Investors should closely monitor the company's cash flow, debt levels, and ability to secure funding for future growth. The high beta of -58.74 suggests extreme volatility relative to the market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
  • Negative P/E ratio of -0.01 reflects the company's current lack of profitability.
  • Profit Margin of -11861.4% highlights significant operational inefficiencies and challenges in achieving profitability.
  • Gross Margin of 100.0% suggests high potential profitability if operational costs are managed effectively.
  • Beta of -58.74 indicates an extremely volatile stock, moving inversely to the market.

Competidores y Pares

Fortalezas

  • Focus on the growing cannabis beverage market.
  • Potential for first-mover advantage in specific regions.
  • Experienced management team with knowledge of the cannabis industry.

Debilidades

  • Limited financial resources compared to larger competitors.
  • Dependence on regulatory approvals for growth.
  • Lack of established brand recognition.

Catalizadores

  • Upcoming: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
  • Ongoing: Increasing consumer acceptance of cannabis-infused beverages could drive demand and revenue growth.
  • Ongoing: Development and launch of new cannabis-infused beverage products could attract new customers.
  • Upcoming: Securing partnerships with established beverage distributors could expand market reach.
  • Ongoing: Positive clinical trial results for cannabis-based therapies could increase investor confidence.

Riesgos

  • Potential: Stringent regulations and licensing requirements could limit market access.
  • Ongoing: Intense competition from larger cannabis companies could erode market share.
  • Potential: Negative public perception of cannabis could hinder demand growth.
  • Ongoing: Limited access to capital and funding could constrain growth plans.
  • Potential: Product recalls or safety concerns could damage brand reputation.

Oportunidades de crecimiento

  • Expansion into New Markets: As cannabis legalization expands across the United States, CaliPharms, Inc. has the opportunity to enter new markets. Each new state represents a potential revenue stream, provided the company can navigate the local regulatory environment. The timeline for this growth is dependent on the pace of legalization efforts and the company's ability to secure licenses and distribution agreements. The market size for cannabis beverages is projected to reach billions of dollars in the coming years.
  • Product Diversification: CaliPharms, Inc. can expand its product line beyond THC and CBD beverages to include other cannabis-infused products, such as edibles, topicals, and concentrates. This diversification would allow the company to cater to a wider range of consumer preferences and increase its market share. The timeline for product diversification depends on the company's R&D capabilities and its ability to obtain regulatory approval for new products. The market for cannabis-infused products is diverse and growing rapidly.
  • Strategic Partnerships: Forming strategic partnerships with established beverage distributors or cannabis retailers can provide CaliPharms, Inc. with access to wider distribution networks and increased brand visibility. These partnerships can accelerate the company's growth and reduce its reliance on direct sales. The timeline for establishing strategic partnerships depends on the company's networking efforts and its ability to negotiate favorable terms. The benefits of strategic partnerships can be significant, including increased revenue and market share.
  • Branding and Marketing: Investing in branding and marketing efforts can help CaliPharms, Inc. establish a strong brand identity and differentiate itself from competitors. Effective marketing campaigns can increase consumer awareness and drive sales. The timeline for building a strong brand depends on the company's marketing budget and its ability to create compelling messaging. A strong brand can command premium pricing and increase customer loyalty.
  • Research and Development: Investing in research and development can enable CaliPharms, Inc. to develop innovative new products and improve the quality and efficacy of its existing products. This can give the company a competitive advantage and attract new customers. The timeline for R&D depends on the company's resources and its ability to conduct successful clinical trials. Successful R&D can lead to patentable products and increased market share.

Oportunidades

  • Expansion into new markets as cannabis legalization progresses.
  • Development of innovative cannabis-infused products.
  • Strategic partnerships with established beverage distributors.

Amenazas

  • Increasing competition from larger cannabis companies.
  • Changing regulations and potential for stricter enforcement.
  • Negative public perception of cannabis.

Ventajas competitivas

  • First-mover advantage in specific regional markets.
  • Proprietary formulations for THC and CBD beverages.
  • Established relationships with cannabis cultivators and distributors.

Acerca de KGET

CaliPharms, Inc., headquartered in Temecula, California, is a participant in the United States' medicinal cannabis industry. The company's primary focus is the development and potential distribution of beverages infused with THC and CBD. CaliPharms, Inc. was originally established under the name Kleangas Energy Technologies, Inc., reflecting an earlier business direction. In January 2017, the company underwent a strategic shift, rebranding itself as CaliPharms, Inc. to align with its new focus on the cannabis market. This transition marked a significant change in business strategy, moving away from energy technologies to capitalize on the emerging opportunities within the medicinal cannabis sector. The company is positioning itself to cater to the growing demand for cannabis-infused products, particularly in the beverage segment. CaliPharms, Inc. is working to establish its presence in a competitive market, navigating the regulatory landscape and consumer preferences within the cannabis industry.

Qué hacen

  • Engages in the medicinal cannabis industry in the United States.
  • Focuses on the development of THC and CBD beverages.
  • Aims to capitalize on the growing market for cannabis-infused products.
  • Navigates the regulatory landscape of the cannabis industry.
  • Seeks to establish a brand presence in the cannabis beverage segment.
  • Works to develop and distribute cannabis-infused beverages.

Modelo de Negocio

  • Develops and potentially distributes THC and CBD-infused beverages.
  • Aims to generate revenue through the sale of these beverages.
  • Focuses on the medicinal cannabis market in the United States.

Contexto de la Industria

CaliPharms, Inc. operates in the rapidly evolving cannabis industry, specifically targeting the infused beverage market. This sector is characterized by changing regulations, increasing competition, and growing consumer acceptance. The market is driven by the increasing legalization of cannabis for medicinal and recreational purposes in various states. CaliPharms faces competition from established players in the beverage industry and emerging cannabis companies. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.

Clientes Clave

  • Consumers seeking medicinal cannabis products.
  • Individuals interested in THC and CBD-infused beverages.
  • Patients with medical conditions that may benefit from cannabis use.
Confianza de la IA: 67% Actualizado: 18 mar 2026

Finanzas

Gráfico e información

Precio de la acción de CaliPharms, Inc. (KGET): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para KGET.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para KGET.

MoonshotScore

57/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de KGET en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Eric Watson

CEO

Eric Watson serves as the Chief Executive Officer of CaliPharms, Inc. Information regarding Mr. Watson's detailed career history, educational background, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive overview of his professional background and qualifications.

Historial: Due to limited information, it is not possible to assess Eric Watson's track record at CaliPharms, Inc. or his previous accomplishments in other roles. An evaluation of his strategic decisions, company milestones achieved under his leadership, and overall performance requires additional data.

Información del mercado OTC de KGET

The OTC Other tier represents the lowest tier of the OTC market, indicating that CaliPharms, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to less stringent regulations and oversight compared to those listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with higher reporting standards. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: As an OTC stock, KGET's liquidity may be limited, potentially leading to wider bid-ask spreads and difficulties in executing large trades without significantly impacting the price. The trading volume may be low, making it challenging to enter or exit positions quickly. Investors should be aware of these liquidity constraints and consider their potential impact on investment outcomes.
Factores de riesgo OTC:
  • Limited liquidity and potential for price volatility.
  • Lack of regulatory oversight and potential for fraud.
  • Uncertainty regarding financial reporting and disclosure.
  • Higher risk of delisting or trading suspension.
  • Potential for limited access to capital and funding.
Lista de verificación de diligencia debida:
  • Verify the company's legal status and registration.
  • Obtain and review the company's financial statements.
  • Assess the company's management team and their experience.
  • Research the company's business model and competitive landscape.
  • Evaluate the company's regulatory compliance and risk factors.
  • Determine the availability of reliable information and disclosures.
  • Understand the liquidity and trading characteristics of the stock.
Señales de legitimidad:
  • Company's registration and good standing with regulatory authorities.
  • Availability of some financial information, even if limited.
  • Active communication with investors and the public.
  • Positive media coverage or industry recognition.
  • Existence of a functional website and contact information.

Lo Que los Inversores Preguntan Sobre CaliPharms, Inc. (KGET)

¿Cuáles son los factores clave para evaluar KGET?

CaliPharms, Inc. (KGET) actualmente tiene una puntuación IA de 57/100, indicando puntuación moderada. Fortaleza clave: Focus on the growing cannabis beverage market.. Riesgo principal a monitorear: Potential: Stringent regulations and licensing requirements could limit market access.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de KGET?

KGET actualmente puntúa 57/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de KGET?

Los precios de KGET se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre KGET?

La cobertura de analistas para KGET incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en KGET?

Las categorías de riesgo para KGET incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Stringent regulations and licensing requirements could limit market access.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de KGET?

La relación P/E para KGET compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está KGET sobrevalorada o infravalorada?

Determinar si CaliPharms, Inc. (KGET) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de KGET?

CaliPharms, Inc. (KGET) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited information available for this company. OTC stocks are inherently riskier.
Fuentes de datos

Popular Stocks